Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zero Candida Technologies's Net Income (Continuing Operations) for the
six
months ended in Jun. 2026 was C$-0.49 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was C$-0.94 Mil.
Zero Candida Technologies (TSXV:ZCT) Net Income (Continuing Operations) Explanation
Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Zero Candida Technologies Net Income (Continuing Operations) Related Terms
Zero Candida Technologies Net Income (Continuing Operations) Historical Data
* Premium members only.
The historical data trend for Zero Candida Technologies's Net Income (Continuing Operations) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zero Candida Technologies Net Income (Continuing Operations) Chart
Zero Candida Technologies Net Income (Continuing Operations) Calculation
Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was C$-0.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income (Continuing Operations) of C$-0.94 Mil mean?
Zero Candida Technologies (TSXV:ZCT) has a Net Income (Continuing Operations) of C$-0.94 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Zero Candida Technologies and its competitors.
Is Zero Candida Technologies' Net Income (Continuing Operations) too high?
Zero Candida Technologies' current Net Income (Continuing Operations) is C$-0.94 Mil. Overall, Zero Candida Technologies has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Zero Candida Technologies' Net Income (Continuing Operations) compare to ABT and SYK?
Zero Candida Technologies' Net Income (Continuing Operations) of C$-0.94 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Zero Candida Technologies and its competitors. Zero Candida Technologies's current Net Income (Continuing Operations) is C$-0.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zero Candida Technologies stock overvalued right now?
Zero Candida Technologies (TSXV:ZCT) has a current Net Income (Continuing Operations) of C$-0.94 Mil. The current Net Income (Continuing Operations) is C$-0.94 Mil. Zero Candida Technologies' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Zero Candida Technologies (TSXV:ZCT), the current Net Income (Continuing Operations) is C$-0.94 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zero Candida Technologies Inc. is a medical device company developing a treatment for vulvovaginal candidiasis, a common fungal infection. Its core technology is a tampon-like intravaginal device that uses controlled blue light to destroy Candida fungus, aiming to offer an alternative to antifungal medication. The device is designed to incorporate artificial intelligence and wireless connectivity, allowing it to transmit treatment and diagnostic data to physicians. The company's target customers are women affected by recurrent or drug-resistant yeast infections, along with the gynecologists and healthcare providers who treat them. It is focused on developing and commercializing its patents and patent applications covering the device. As a development-stage company, it does not yet generate product revenue and depends on financing to fund research, clinical testing, and regulatory approval efforts.
15GF Score
Get the complete analysis for TSXV:ZCT
Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZCT has been successfully added to your 
